Merus’ Phase I/II zenocutuzumab asset to treat tumours harbouring NRG1 fusions saw its Phase Transition Success Rate (PTSR) jump five points to 28%. The update occurred on 7 June on the heels of a pooled data analysis from an ongoing trial being presented at the 2021 ASCO Annual Meeting. The virtual conference took place 4–8 June.

PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. In the 250-patient Phase I/II eNRGy study among 45 patients, 34 reported tumour reduction and the overall response rate (ORR) was 29% (abstract no:TPS3145). The estimated primary completion date for the study is in September 2021, according to Zenocutuzumab acts by binding to Her2 and blocking Her3 interaction with NRG1 or NRG1-fusion proteins, thus potentially being effective against NRG1+ cancers.

The data update also resulted in a modest one-point increase in the drug’s Likelihood of Approval (LoA) taking it to 8%. LoA is identified via GlobalData’s analysis using a combination of machine learning and a proprietary algorithm and is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

Merus has a market cap of $888.6m.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.